AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6135635
Drug: Control test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control test (saline infusion)
Trial: 31580005
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose resulting in 24-hour lasting purpura
Trial: 31580005
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose resulting in vessel disappearance observed by dermoscope
Trial: 25249415
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g cinnamon twice a day for 12 weeks
Trial: 22251435
Drug: Infliximab induction
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab induction therapy (5 or 10 mg/kg every 8 weeks beginning at week 14)
Trial: 22251435
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment with CRP normalization (decrease from 0.5 mg/dL at baseline to < 0.5 mg/dL at week 14)
Trial: 22251435
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment at week 14 with low CRP levels
Trial: 15652906
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone analogue (1 month before procedure)
Trial: 15652906
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone analogue
Trial: 14563391
Drug: Tin(II) chloride
RxNorm normalized name: Tin(II) fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tin(II) chloride at concentrations of <0.5, 161, 264, and 529 mg/kg in 250 ml tomato juice
Trial: 14563391
Drug: Tin migrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tin migrated from packaging at concentrations of <0.5, 201, and 267 mg/kg in 250 ml tomato soup
Trial: 10397651
Drug: HA-coated TPS
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HA-coated TPS implants
Trial: 10397651
Drug: TPS cylinder
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TPS cylinder implants
Trial: 28704492
Drug: Pretreatment MMP9
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretreatment MMP9 levels in CSF (median [interquartile range], 254 [115‐389] ng/mL in good outcome group)
Trial: 28704492
Drug: Pretreatment MMP9
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretreatment MMP9 levels in CSF (median [interquartile range], 192 [60‐383] ng/mL in poor outcome group)
Trial: 28704492
Drug: TIMP1 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMP1 levels in CSF (1239 [889‐1511] ng/mL in good outcome group)
Trial: 28704492
Drug: TIMP1 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMP1 levels in CSF (1522 [934‐1949] ng/mL in poor outcome group)
Trial: 8224655
Drug: Propranolol (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (continuous administration to reduce resting heart rate by 25%)
Trial: 8224655
Drug: Sclerotherapy (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy (weekly intravariceal sessions using 5% ethanolamide oleate until varices disappeared)
Trial: 26881516
Drug: Concomitant boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant boost therapy with cisplatin (Arm B)
Trial: 16870801
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation as an adjunct to standard pharmacotherapy
Trial: 15295717
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg + Lisinopril 20 mg
Trial: 11738913
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of betamethasone and neomycin eyedrops
Trial: 15102426
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (ibuprofen, paracetamol, placebo)
Trial: 2680896
Drug: Metronidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (2 g twice at an interval of two days)
Trial: 2680896
Drug: Placebo (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inert but identical tablets)
Trial: 22238470
Drug: Miltefosine (1.8‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltefosine (1.8‐2.5 mg/kg/d for 28 days; by mouth)
Trial: 22238470
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (20 mg Sb/kg/d for 20 days; intramuscular)
Trial: 20921440
Drug: Perhexiline 100
RxNorm normalized name: perhexiline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perhexiline 100 mg (n=24)
Trial: 10618544
Drug: Engerix-B 10
RxNorm normalized name: Engerix-B 10 MCG per 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B 10 microg vaccine (EB)
Trial: 9093239
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment and therapy for opportunistic infections
Trial: 9093239
Drug: HIV-associated non-Hodgkin
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-associated non-Hodgkin lymphomas treatment
Trial: 9093239
Drug: HIV-associated central
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-associated central nervous system lymphomas treatment
Trial: 9093239
Drug: Hodgkin's disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hodgkin's disease treatment in HIV-infected individuals
Trial: 8292067
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated multiple-unit formulation (Diclo-Puren 50)
Trial: 8292067
Drug: Single-unit dosage
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-unit dosage form (reference)
Trial: 2880294
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg per kilogram of body weight per day) with decongestant-antihistamine
Trial: 2880294
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg per kilogram of body weight per day) without decongestant-antihistamine
Trial: 29087443
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment included in the programme (Group A)
Trial: 29087443
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment plus attendance at self-help groups (Group B)
Trial: 16419568
Drug: SPECT scans
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT scans after i.v. injection of 99mTc‐ECD of 0.3 mCi/kg b.m.
Trial: 12591833
Drug: Subcutaneous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin twice daily for three months
Trial: 2882776
Drug: Carteolol (beta-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol (beta-adrenoceptor blocker)
Trial: 29072044
Drug: Focused shock
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused shock wave therapy
Trial: 25539757
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) + olanzapine (5 mg/day) for 3 months
Trial: 19212708
Drug: Docetaxel (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (45 mg/m²) combined with 5‐FU/leucovorin
Trial: 19212708
Drug: Irinotecan (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (180 mg/m²) combined with 5‐FU/leucovorin
Trial: 12500022
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg once daily)
Trial: 15829533
Drug: Daily budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily budesonide therapy
Trial: 15829533
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with budesonide
Trial: 15829533
Drug: Daily zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily zafirlukast therapy
Trial: 9282581
Drug: Enalapril in
RxNorm normalized name: enalapril Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril in combination with bronchodilators, diuretics, antibiotics and/or steroids
Trial: 9282581
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with diuretics, steroids and antibiotics alone
Trial: 1713663
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg via epidural administration
Trial: 1713663
Drug: Hydromorphone 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.75 mg via epidural administration
Trial: 24711552
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg per day)
Trial: 20329618
Drug: Zengjing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zengjing Capsule No. 1 (ZJC1)
Trial: 17259038
Drug: Breast-feeding before,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-feeding before, during, and after the injection
Trial: 2658640
Drug: Cefuroxime 1
RxNorm normalized name: cefuroxime 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1 g
Trial: 51285
Drug: Bromocriptine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (mean 46.9 mg daily)
Trial: 26488347
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day (non-bulimic patients)
Trial: 17146981
Drug: Adaptive allocation
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive allocation treatment
Trial: 11256775
Drug: Dalteparin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (120 IU/kg twice daily)
Trial: 9167318
Drug: Fluvoxamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine plus cognitive behaviour therapy
Trial: 9167318
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cognitive behaviour therapy
Trial: 9167318
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy alone
Trial: 8245990
Drug: Warfarin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin anticoagulation (6-12 weeks course)
Trial: 31978933
Drug: MDMA (0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (0.75, 1.5 mg/kg)
Trial: 24448644
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (20 or 40 IU)
Trial: 23140055
Drug: Medication (Ranitidine)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Ranitidine)
Trial: 23140055
Drug: Medication (Ranitidine)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Ranitidine) (1 month follow-up)
Trial: 12552508
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 1.2 g twice a day for 4 weeks
Trial: 10651655
Drug: Eudragit-coated gelatine
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eudragit-coated gelatine capsule containing 111In-labelled amberlite resin
Trial: 9007589
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg on the first day then 200 mg)
Trial: 9007589
Drug: Amphotericin B/5-flucytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphotericin B/5-flucytosine (1.0-1.5 mg/kg body weight every other day and 3 x 2.5 g flucytosine/day)
Trial: 6094438
Drug: Cefotaxime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (50 mg/kg/dose every 6 h for 10 to 14 days)
Trial: 6094438
Drug: Ampicillin and
RxNorm normalized name: Ampicillin and sulbactam only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin and chloramphenicol (standard doses)
Trial: 31362183
Drug: Oxytocin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (24 IU intranasal application)
Trial: 21294410
Drug: Single-injection paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection paravertebral block (PVB) with 0.3 ml/kg of 0.5% plain bupivacaine at T4 paravertebral space followed by general anesthesia
Trial: 18021336
Drug: Praziquantel 20
RxNorm normalized name: PRAZIQUANTEL 20 kg in 20 kg POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 20 mg/kg alone
Trial: 18021336
Drug: Praziquantel 20
RxNorm normalized name: PRAZIQUANTEL 20 kg in 20 kg POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 20 mg/kg with ketoconazole 400 mg daily for 5 days
Trial: 11911101
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution intake during labour
Trial: 9866670
Drug: Recommended levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended levels of antidepressant treatment (doses recommended by the Agency for Health Care Policy and Research for 90 days or more)
Trial: 9866670
Drug: Less-than-recommended levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-than-recommended levels of antidepressant treatment
Trial: 9866670
Drug: Minimum recommended
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum recommended levels of antidepressant treatment
Trial: 7533825
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) - lenograstim 5 micrograms/kg/d between cycles
Trial: 7533825
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - VICE chemotherapy alone
Trial: 26884620
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil (0.2 mg/kg bolus followed by 0.2 mg/kg/h for 24 h)
Trial: 11888823
Drug: Iodixanol (320mgI.ml(‐1))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (320mgI.ml(‐1))
Trial: 11888823
Drug: Iopromide (300mgI.ml(‐1))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (300mgI.ml(‐1))
Trial: 9598509
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with a gonadotropin‐releasing hormone agonist for 3 months before radical prostatectomy
Trial: 7934431
Drug: Sumatriptan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (16 mg, subcutaneous administration)
Trial: 3793199
Drug: Domperidone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (0.3 mg/kg)
Trial: 26004393
Drug: S-1 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administration for more than 1 year
Trial: 26004393
Drug: S-1 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administration periods of 24 months or longer
Trial: 26004393
Drug: S-1 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administration
Trial: 19307517
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D (with or without calcium)
Trial: 19307517
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of oral vitamin D (>400 IU/d)
Trial: 16870768
Drug: Tefibazumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tefibazumab (20 mg/kg as a single infusion)
Trial: 14997746
Drug: Breast conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservation treatment
Trial: 14997746
Drug: Breast conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservation treatment in ductal carcinoma in situ
Trial: 9476185
Drug: Ranitidine, prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, prescribed to 73.9% of patients receiving treatment.
Trial: 9476185
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment motivated by fear of stress mucosal lesions (28%) and therapy with other drugs (56%).
Trial: 9476185
Drug: General prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General prescription practices for peptic diseases.
Trial: 2959623
Drug: GTF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTF vaccine with aluminum phosphate (AP)
Trial: 24731231
Drug: Exogenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous glutamine supplementation (L-alanyl-L-glutamine, 0.28 g/kg during 20 hours)
Trial: 18940387
Drug: Transdermal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐estradiol gel
Trial: 2481772
Drug: Nicardipine (NIC)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NIC) 20 mg t.i.d.
Trial: 2481772
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) 50 mg b.i.d.
Trial: 23098686
Drug: AZD9164 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9164 100 μg
Trial: 23098686
Drug: AZD9164 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9164 400 μg
Trial: 23098686
Drug: AZD9164 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9164 1200 μg
Trial: 21421502
Drug: Urokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase and argatroban administered regionally via small saphenous vein catheter
Trial: 21421502
Drug: Urokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase and argatroban administered via peripheral vein (control)
Trial: 16893433
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg t.i.d. for 12 weeks
Trial: 15330957
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural morphine 0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline (TEP group, n = 16)
Trial: 15330957
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion at 0.02 mg x kg(‐1) h(‐1) (INF group, n = 16)
Trial: 9009045
Drug: Exposure with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure with response prevention (standard behavior therapy protocol including in vivo and imagery exposure)
Trial: 8390952
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon alfa‐2b (6 million units)
Trial: 8390952
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose interferon alfa‐2b (3 million units)
Trial: 24685847
Drug: Methotrexate 15
RxNorm normalized name: methotrexate 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 mg weekly for 12 weeks
Trial: 8958191
Drug: Cilazapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (1 mg/day)
Trial: 1286486
Drug: Etodolac 600
RxNorm normalized name: etodolac 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 600 mg/day
Trial: 3927650
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg L-Deprenyl per day
Trial: 3927650
Drug: L-Deprenyl
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Deprenyl
Trial: 29688628
Drug: Verinurad 10
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 10 mg + Febuxostat 40 mg
Trial: 29688628
Drug: Verinurad 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 2.5 mg + Febuxostat 80 mg
Trial: 29688628
Drug: Verinurad and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad and Febuxostat combination